Literature DB >> 7505422

Delta F508 genotype does not predict disease severity in an ethnically diverse cystic fibrosis population.

L A Lester1, J Kraut, J Lloyd-Still, T Karrison, C Mott, C Billstrand, A Lemke, C Ober.   

Abstract

OBJECTIVE: As part of a study to determine population-based frequencies of CFTR mutations in an ethnically diverse, midwestern cystic fibrosis (CF) population, clinical histories were studied in 119 CF patients.
METHODOLOGY: We sought to examine the association between genotype as characterized by the delta F508 and 11 other commonly occurring mutations and clinical parameters including age at diagnosis, clinical presentation, sweat chloride level, chest roentgenogram score, clinical scores, pulmonary function test results, percent weight for height, and presence of associated CF complications.
RESULTS: Age at diagnosis of CF was significantly associated with homozygosity for delta F508 (mean age at diagnosis +/- SE: 1.7 +/- 0.3 years for delta F508/delta F508 vs 3.9 +/- 0.9 years for delta F508/other and other/other; P = .03). No other age-adjusted clinical parameter was significantly associated with delta F508 or any other genotype.
CONCLUSION: These data suggest that in this sample of CF patients, delta F508 genotype is not predictive of disease severity. The lack of association between disease severity and genotype in this ethnically diverse sample may reflect the presence of more severe undetected mutations in our sample, or the effects of modifying genes at other, non-CF loci.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7505422

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  11 in total

1.  Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype.

Authors:  R B Parad; C J Gerard; D Zurakowski; D P Nichols; G B Pier
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  New modifier loci in cystic fibrosis.

Authors:  Heiko Witt
Journal:  Nat Genet       Date:  2011-06       Impact factor: 38.330

3.  Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis.

Authors:  J Hull; A H Thomson
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

Review 4.  Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?

Authors:  Rainer Büscher; Hartmut Grasemann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-10-11       Impact factor: 3.000

5.  Amyloid goitre and hypothyroidism secondary to cystic fibrosis.

Authors:  R Alvarez-Sala; C Prados; J Sastre Marcos; F García Río; B Vicandi; A de Ramón; J Villamor
Journal:  Postgrad Med J       Date:  1995-05       Impact factor: 2.401

Review 6.  Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

Authors:  C Castellani; H Cuppens; M Macek; J J Cassiman; E Kerem; P Durie; E Tullis; B M Assael; C Bombieri; A Brown; T Casals; M Claustres; G R Cutting; E Dequeker; J Dodge; I Doull; P Farrell; C Ferec; E Girodon; M Johannesson; B Kerem; M Knowles; A Munck; P F Pignatti; D Radojkovic; P Rizzotti; M Schwarz; M Stuhrmann; M Tzetis; J Zielenski; J S Elborn
Journal:  J Cyst Fibros       Date:  2008-05       Impact factor: 5.482

7.  Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.

Authors:  Thierry Ntimbane; Blandine Comte; Geneviève Mailhot; Yves Berthiaume; Vincent Poitout; Marc Prentki; Rémi Rabasa-Lhoret; Emile Levy
Journal:  Clin Biochem Rev       Date:  2009-11

8.  Classic respiratory disease but atypical diagnostic testing distinguishes adult presentation of cystic fibrosis.

Authors:  Claire L Keating; Xinhua Liu; Emily A Dimango
Journal:  Chest       Date:  2009-12-04       Impact factor: 9.410

Review 9.  Chronic pancreatitis and cystic fibrosis.

Authors:  H Witt
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

10.  Association between insurance variability and early lung function in children with cystic fibrosis.

Authors:  Kimberly M Dickinson; Kevin J Psoter; Kristin A Riekert; Joseph M Collaco
Journal:  J Cyst Fibros       Date:  2021-06-24       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.